Clinical trials: Digestive System Malignancies
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Carcinoma, Hepatocellular
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol…
- Trial name
- NCT00857805
- Testing
- Transarterial Chemoembolization, Proton Beam Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Loma Linda University
Gastric Cancer
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in…
- Trial name
- FIGHT (NCT03694522)
- Testing
- Bemarituzumab, Modified FOLFOX6
- Where
- 189 sites in United States, Australia and 16 more
- Volunteers
- 155 people
- Sponsor
- Five Prime Therapeutics, Inc.
Esophageal Cancer
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as cetuximab may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00096031
- Testing
- cetuximab
- Where
- 152 sites in United States
- Volunteers
- 63 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and…
- Trial name
- NCT01478594
- Testing
- Tivozanib, Bevacizumab, mFOLFOX6
- Where
- 73 sites in United States, Australia and 10 more
- Volunteers
- 265 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Colorectal Cancer
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114231
- Testing
- capecitabine, oxaliplatin, neoadjuvant therapy
- Where
- 67 sites in United States
- Volunteers
- 90 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastrointestinal Cancer
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents.
- Trial name
- IMPACT-GI (NCT04736472)
- Testing
- Pharmacogenetic test
- Where
- 3 sites in United States
- Volunteers
- 552 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Cancer
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated effectiveness against pancreatic cancer in laboratory…
- Trial name
- NCT01663272
- Testing
- CABOZANTINIB, gemcitabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Hepatocellular Carcinoma
Impact of Y90 Radiation Segmentectomy on HCC
The aim of this pilot study is to assess the efficacy of radiation segmentectomy with Theraspheres in patients with unresectable hepatocellular carcinoma that would qualify for thermal ablation as per the BCLC guidelines, but are…
- Trial name
- NCT03248375
- Testing
- Radiation Segmentectomy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Irritable Bowel Syndrome
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
This FTIH study is designed to assess the safety, tolerability and pharmacokinetic (PK) of escalating single and repeat oral doses of GSK3352589 in normal healthy volunteers.
- Trial name
- NCT03154086
- Testing
- GSK3352589
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Oesophageal Cancer
Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer
This is a feasibility study testing the use of the Cytosponge™ device in patients with known oesophageal cancer treated with pre-operative or definitive chemoradiation.
- Trial name
- CYTOFLOC (NCT03529669)
- Testing
- Cytosponge™
- Where
- 11 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Rectal Cancer
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
- Trial name
- BRANCH (NCT01481545)
- Testing
- Radiation therapy, Oxaliplatin, Raltitrexed
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Cancer, Peritoneal Neoplasms
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
The purposes of this study are: 1. To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) weekly of topotecan in combination with standard dose gefitinib in patients with relapsed, platinum-resistant…
- Conditions
- Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
- Trial name
- NCT00317772
- Testing
- Topotecan, Gefitinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Cancer
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
The main purpose of this study is to study the safety and effectiveness of ADXS11-001 when combined with standard chemotherapy and radiation treatment for anal cancer.
- Trial name
- 276 (NCT01671488)
- Testing
- Treatment, 5FU, Mitomycin
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Liver Metastases, Recurrent Colon Cancer
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer
- Trial name
- NCT01320683
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Pancreatic Cancer, Cancer of Pancreas
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine.
- Conditions
- Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
- Trial name
- NCT02352831
- Testing
- Tosedostat, Capecitabine, Fresh tissue biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Metastatic Colorectal Cancer
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Background: Colorectal cancer (CRC) is a major public health problem in the U.S. and worldwide, and 5-year survival with widespread metastatic disease is less than 5%.
- Trial name
- NCT00326495
- Testing
- Cetuximab, BAY 43-9006
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Cancer, Lung Cancer
Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
The goal of this clinical research study is to evaluate the effectiveness of melatonin for the management of poor appetite and weight loss in advanced cancer patients.
- Trial name
- NCT00513357
- Testing
- Melatonin
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Bladder Cancer
Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)
This is a proof-of-concept pilot randomized clinical trial to test the feasibility of the innovative Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) to enhance personalized supportive care for cancer…
- Conditions
- Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- PRISMS (NCT04492007)
- Testing
- Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.